List view / Grid view
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Aparajita Dubey summarises the recent trends in upstream bioprocessing and highlights the challenges and solutions involved in its process development.
Upstream bioprocessing is the epicentre of biologics development, wherein scientists piece together a series of carefully chosen processes with contributing components and parameters to enable the production of highly effective biotherapeutics. Unjulie Bhanot explains why an effective data management system is vital in this quest for the next big therapeutic.
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.
Vernalis Research is based at Granta Park in Cambridge, UK and specialises in the development and application of fragment- and structure-based drug discovery methods. Nikki Withers met with Vernalis’ Research Director, James Murray, to discuss the company’s innovative approach to target discovery and how they sustain symbiotic collaborations to progress…
CRISPR is the buzzword of the moment in the drug discovery industry – mainly due to its potential to correct disease-causing mutations. However, those using the technology need to be mindful that it is used responsibly, and possible risks are considered before use. Mark Behlke discusses the potential of CRISPR…
Steven van Helden, Chief Technology Officer at Pivot Park Screening Centre (PPSC), relies on efficient microplate readers for effective hit discovery.
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
There is still much to be done regarding how training is delivered and monitored in core technologies such as flow cytometry. Here, Derek Davies outlines the approaches his team at The Francis Crick Institute are taking to train users of such technologies to ensure quality data is obtained and best…
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
As research moves forward at a rapid pace and data is being generated in larger quantities than ever before, one problem the scientific community faces is reproducibility.
Pharmaceutical companies are under increasing pressure to get novel drugs to market as quickly as possible. Here, Sheraz Gul discusses how integrating processes could help streamline drug discovery in the future.
Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.
